BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,230,968 | +146.4% | 253,136 | +195.4% | 0.01% | +125.0% |
| Q2 2023 | $6,994,222 | +11894.9% | 85,682 | -89.1% | 0.00% | -87.9% |
| Q1 2023 | $58,310 | +98.3% | 785,953 | +121.5% | 0.03% | +106.2% |
| Q4 2022 | $29,409 | -99.9% | 354,846 | +322.6% | 0.02% | +14.3% |
| Q3 2022 | $23,847,000 | +896.5% | 83,968 | +1116.6% | 0.01% | +1300.0% |
| Q2 2022 | $2,393,000 | -67.2% | 6,902 | -59.0% | 0.00% | -66.7% |
| Q1 2022 | $7,290,000 | -73.7% | 16,833 | -68.6% | 0.00% | -78.6% |
| Q4 2021 | $27,744,000 | -40.1% | 53,629 | -43.9% | 0.01% | -50.0% |
| Q3 2021 | $46,320,000 | +1037.5% | 95,590 | +957.1% | 0.03% | +1300.0% |
| Q2 2021 | $4,072,000 | -94.1% | 9,043 | -95.0% | 0.00% | -96.0% |
| Q1 2021 | $69,588,000 | +232.2% | 182,201 | +176.2% | 0.05% | +233.3% |
| Q4 2020 | $20,945,000 | +34.2% | 65,958 | +4.7% | 0.02% | -25.0% |
| Q3 2020 | $15,609,000 | +244.4% | 63,007 | +267.2% | 0.02% | +185.7% |
| Q2 2020 | $4,532,000 | +124.9% | 17,161 | +61.5% | 0.01% | +40.0% |
| Q1 2020 | $2,015,000 | -22.4% | 10,626 | -10.2% | 0.01% | +66.7% |
| Q4 2019 | $2,597,000 | -83.2% | 11,828 | -85.0% | 0.00% | -87.5% |
| Q3 2019 | $15,474,000 | -40.9% | 79,085 | -37.0% | 0.02% | -38.5% |
| Q2 2019 | $26,186,000 | -37.2% | 125,598 | -40.2% | 0.04% | -37.1% |
| Q1 2019 | $41,702,000 | +8606.1% | 210,031 | +6241.5% | 0.06% | +6100.0% |
| Q4 2018 | $479,000 | -97.1% | 3,312 | -96.0% | 0.00% | -95.2% |
| Q3 2018 | $16,756,000 | +58.4% | 82,094 | +17.2% | 0.02% | +50.0% |
| Q1 2018 | $10,581,000 | +19.1% | 70,053 | +2.1% | 0.01% | +16.7% |
| Q4 2017 | $8,887,000 | -51.6% | 68,597 | -54.8% | 0.01% | -57.1% |
| Q3 2017 | $18,355,000 | +2154.9% | 151,835 | +1796.5% | 0.03% | +2700.0% |
| Q1 2017 | $814,000 | -79.6% | 8,006 | -79.4% | 0.00% | -87.5% |
| Q4 2016 | $3,996,000 | -66.8% | 38,856 | -64.6% | 0.01% | -60.0% |
| Q3 2016 | $12,036,000 | +368.5% | 109,916 | +382.4% | 0.02% | +233.3% |
| Q2 2016 | $2,569,000 | -76.3% | 22,785 | -80.1% | 0.01% | -77.8% |
| Q1 2016 | $10,831,000 | +2053.3% | 114,594 | +1950.3% | 0.03% | +2600.0% |
| Q4 2015 | $503,000 | -96.3% | 5,589 | -96.1% | 0.00% | -96.2% |
| Q3 2015 | $13,422,000 | +667.8% | 145,161 | +717.9% | 0.03% | +766.7% |
| Q2 2015 | $1,748,000 | -42.7% | 17,747 | -41.7% | 0.00% | -50.0% |
| Q1 2015 | $3,051,000 | +11.3% | 30,420 | +2.6% | 0.01% | 0.0% |
| Q4 2014 | $2,741,000 | – | 29,662 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |